Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 7/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | HPGD | P15428 | 7/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.35 |
| ▸ | CASP1 | P29466 | 6/20 | 0.35 |
| ▸ | CASP7 | P55210 | 6/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | GLA | P06280 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 5/20 | 0.35 |
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | USP2 | O75604 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900974 | 0.91 | ALDH1A1 (0.41) | LCKTNK2OPRM1OPRL1ALDH1A1 | |
| SCHEMBL14118682 | 0.90 | AKT1 (0.41) | LCKTNK2OPRM1OPRL1ALDH1A1 | |
| SCHEMBL1903305 | 0.84 | AKT1 (0.46) | AKT1 | |
| SCHEMBL12095366 | 0.82 | KDM4E (0.37) | LCKTNK2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL14118620 | 0.82 | CKS1B (0.47) | OPRM1AKT1 | |
| SCHEMBL1905448 | 0.81 | TACR3 (0.38) | TNK2CYP3A4TACR3AKT1EGFR | |
| SCHEMBL14119122 | 0.80 | CKS1B (0.48) | OPRM1AKT1 | |
| SCHEMBL1908151 | 0.80 | TACR3 (0.37) | KDM4ETACR3AKT1KMT2A | |
| SCHEMBL1902848 | 0.79 | TACR3 (0.37) | TNK2TACR3AKT1 | |
| SCHEMBL1903999 | 0.78 | AURKA (0.36) | ALDH1A1HSD17B10ALOX15TACR3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | LCK 428/4885TNK2 33/4885OPRM1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.